Created On: 2020-07-15
Record Count: 5
- Personal Care Products
- Hair loss
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 25899
The rights granted apply to the healthcare industry relating to reducing the presence of infectious viruses from human blood.
IPSCIO Record ID: 25932
IPSCIO Record ID: 28991
U.S. Patent No. 5,527,772, 5,840,690, 6,066,618
IPSCIO Record ID: 227271
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.
The agreement is exclusive except for the non-exclusive license granted to the U.S. government
Angiogenesis And Tumor Growth In Vivo.
2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth
2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo
Anti-Angiogenesis for the Treatment of Cancer
In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.
IPSCIO Record ID: 1370
Licensor is willing to grant Licensee rights to the Licensor IP in the Territory with a limited field of use of intracavity radiation therapy (brachytherapy) of the brain (â€œExclusive Field of Useâ€).
GliaSiteÂ® Radiation Therapy System (RTS) is for the treatment of brain cancer, i.e. primary and recurrent gliomas and metastic brain tumors. Specifically, the intended use of GliaSiteÂ® RTS is the management of surgically resectable brain tumors where adjuvant radiation therapy of the post-resection tissue bed is indicated.